Regulatory Conditions on Novo Holdings’ $16.5 Billion Catalent Deal Fulfilled, Companies Say
All regulatory closing conditions related to Novo Holdings’ $16.5 billion acquisition of U.S. contract drug maker Catalent (NYSE: CTLT) had […]
Novo Holdings
Novo Holdings Gains EU Antitrust Approval for $16.5 Billion Catalent Acquisition
BRUSSELS – On Friday, Novo Holdings gained unconditional EU antitrust approval for its $16.5 billion acquisition of U.S. contract drug
Novo Holdings Gains EU Antitrust Approval for $16.5 Billion Catalent Acquisition Read More »
Novo Holdings Nears EU Approval for $16.5 Billion Catalent Acquisition: Source
BRUSSELS/LONDON – Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S.
Novo Holdings Nears EU Approval for $16.5 Billion Catalent Acquisition: Source Read More »
EU Regulators Quiz Novo Nordisk, Catalent Rivals on $16.5 Billion Deal
BRUSSELS/LONDON – EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of
EU Regulators Quiz Novo Nordisk, Catalent Rivals on $16.5 Billion Deal Read More »
Consumer Groups Urge FTC to Block Novo Holdings-Catalent Deal
NEW YORK – On Thursday, U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission to
Consumer Groups Urge FTC to Block Novo Holdings-Catalent Deal Read More »
